Protara Therapeutics EBITDA 2011-2026 | TARA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Protara Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-48.8 M	-43.3 M	-66.8 M	-47.4 M	-34.2 M	-15 M	-21.3 M	-30.2 M	-28.6 M	-20.8 M	-7.55 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-7.55 M	-66.8 M	-33.1 M

Quarterly EBITDA Protara Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-14 M	-	-	-	-11.8 M	-	-	-	-9.66 M	-	-7.8 M	-8.6 M	-10.8 M	-	-10.8 M	-12.7 M	-13.5 M	-	-7.99 M	-7.22 M	-10.1 M	-	-2.25 M	-1.41 M	-1.35 M	-	-4.6 M	-4.97 M	-6.33 M	-	-12.2 M	-5.91 M	-6.44 M	-	-7.08 M	-7.8 M	-6.8 M	-	-5.05 M	-4.96 M	-4.61 M	-	155 K	-2.5 M	-1.93 M	-	-1.89 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
155 K	-14 M	-6.87 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	-35.2 M	$ 1.9	-3.11 %	$ 107 M	China
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.31	-4.06 %	$ 7.96 B	Australia
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Amphastar Pharmaceuticals AMPH	234 M	$ 25.87	-0.79 %	$ 1.25 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-452 M	$ 215.29	4.59 %	$ 5 B	Danmark
BioNTech SE BNTX	15.3 B	$ 105.97	-2.78 %	$ 27.2 B	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aytu BioScience AYTU	-2.45 M	$ 2.71	1.88 %	$ 17 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Arrowhead Pharmaceuticals ARWR	121 M	$ 64.74	1.41 %	$ 8.66 B	USA
Brickell Biotech BBI	-6.32 M	-	-5.38 %	$ 6.06 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 3.96	-1.0 %	$ 8.62 B	Israel
BeiGene, Ltd. BGNE	-396 M	-	0.49 %	$ 251 B	Cayman-islands
Burford Capital Limited BUR	242 M	$ 9.63	-0.93 %	$ 1.56 B	Britain
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Adaptimmune Therapeutics plc ADAP	-130 M	-	-15.15 %	$ 60.3 M	Britain
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 2.97	3.12 %	$ 908 M	Israel
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Biogen BIIB	673 M	$ 164.87	0.27 %	$ 24 B	USA
Bio-Path Holdings BPTH	-15.8 M	-	-	$ 100 K	USA
BioVie BIVI	-17.8 M	$ 1.23	2.07 %	$ 1.82 M	USA
Baudax Bio BXRX	-56.6 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	-115 M	-	-10.95 %	$ 876 K	USA
Arena Pharmaceuticals ARNA	-620 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA